PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer

Area of Science:

• Oncology
• Immunology
• Drug Delivery

Background:

• Targeting immune checkpoints like programmed death ligand-1 (PDL1) is a key anti-cancer strategy.
• Limitations include transient PDL1 expression and poor tumor stroma penetration of anti-PDL1 therapies.

Purpose of the Study:

• To develop a novel conjugate, PDL1-Dox, combining a PDL1 antibody (PDL1 AB) with Doxorubicin (Dox).
• To overcome limitations of anti-PDL1 therapy by enhancing tumor penetration and efficacy.

Main Methods:

• Conjugation of PDL1 AB and Dox via a hydrazone linker with a polyethylene glycol (PEG) spacer.
• Assessment of PDL1-Dox in breast cancer models for cell killing, tumor spheroid disruption, apoptosis induction, and T cell activation (IFN-γ release).
• Optical imaging to evaluate tumor targeting and penetration.

Main Results:

• PDL1-Dox demonstrated significant cell killing, tumor spheroid disruption, and apoptosis induction in breast cancer cells.
• Significant release of interferon-gamma (IFN-γ) indicated enhanced T cell activation.
• Optical imaging confirmed selective tumor targeting and penetration of the construct into the tumor core.

Conclusions:

• PDL1-Dox conjugate effectively targets tumors and penetrates the stroma, overcoming limitations of conventional anti-PDL1 therapy.
• The drug delivery system shows potential for enhanced anti-cancer efficacy through improved tumor penetration and immune modulation.